BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

Exclusion Criteria

• •Known central nervous system lymphoma or leukemia.
• •Known prolymphocytic leukemia or history of, or currently suspected, Richter's syndrome.
• •Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.
• •History of significant cardiovascular disease.
• •Severe or debilitating pulmonary disease.
• •History of severe allergic or anaphylactic reactions to monoclonal antibody therapy.
• •Prior Bruton tyrosine kinase inhibitor treatment.
• •Used medications which were strong cytochrome P450 (CYP) 3A inhibitors and strong CYP3A inducers.
• •Vaccination with a live vaccine within 28 days of the initiation of treatment.
• •Allogeneic stem cell transplantation within 6 months, or had active graft versus host disease requiring ongoing immunosuppression.
• •Receipt of the following treatment prior to first administration of zanubrutinib, corticosteroids given with anti-neoplastic intent within 7 days, chemotherapy or radiotherapy within 3 weeks, monoclonal antibody within 4 weeks.
• •Participated in any investigational drug study within 28 days of study entry, or not recovered from non-hematologic toxicity of any prior chemotherapy up to ≤ Grade 1 (except for alopecia).
• •History of other active malignancies within 2 years of study entry.
• •Major surgery in the past 4 weeks.
• •Active symptomatic fungal, bacterial and/or viral infection including evidence of infection with human immunodeficiency virus, human T cell lymphotropic virus seropositive status.
• •Inability to comply with the study procedures.
• •Pregnant or nursing women.
• •Any illness or condition that in the opinion of the investigator may have affected the safety of treatment or evaluation of any study's endpoints.